Biologics, specifically antibody therapeutics, have significant human value to fight disease. Antibody therapeutics allow for targeted correction of pathological processes, leading to mitigation or correction of disease. Five of the top ten drugs worldwide are based on monoclonal antibodies. Abpro’s antibodies, generated from our DiversImmune platform, are perfectly suited to treat disease.
We have partnered with leading companies to successfully develop many therapeutic antibodies against traditionally difficult targets. Please contact us to discuss more.